

RESEARCH ARTICLE

Evidence-Based Multimodal Management of Severe Post-Asphyxial Cerebral Palsy in a Turkish Girl from Sweden

Aamir Jalal Al-Mosawi

*The National Training and Development Center and Baghdad Medical City, Baghdad, Iraq***Received: 12-01-2026; Revised: 16-02-2026; Accepted: 09-03-2026****ABSTRACT**

Severe perinatal asphyxia is a major cause of cerebral palsy and neurodevelopmental disability. We report the case of a 22-month-old girl who developed cerebral palsy and developmental delay following hypoxic-ischemic encephalopathy at birth. The patient initially underwent unregulated stem cell therapy abroad without benefit. Based on published evidence and our prior clinical experience with neuroprotective agents, she was treated sequentially with Cerebrolysin, Citicoline, Piracetam, collagen hydrolysate, and nutritional support. Improvements were observed in motor strength, vocalization, and cognitive responsiveness across successive treatment courses. This case highlights the importance of evidence-based medicine in guiding rational therapeutic interventions in complex neurological disorders and in resisting unproven alternative approaches.

Keywords: Cerebral palsy, cerebrolysin, citicoline, evidence-based medicine, piracetam, refractory epilepsy

INTRODUCTION

Hypoxic-ischemic encephalopathy (HIE) is one of the most devastating perinatal complications, with survivors often facing cerebral palsy, intellectual disability, or epilepsy.

In recent years, families have increasingly sought unregulated “stem cell” interventions, which lack reproducible evidence of benefit. In contrast, evidence-based medicine (EBM) integrates clinical expertise, the best available evidence, and patient/family values to optimize care and avoid unscientific approaches.^[1-13]

The practice of EBM requires integration of^[14]:

1. Best available research evidence
2. Clinical expertise
3. Patient and caregiver values.

We report the case of a young girl with severe cerebral palsy after birth asphyxia who demonstrated

developmental gains with an evidence-based multimodal pharmacological program, building on our previous experience with the treatment of cerebral palsy and other neurological disorders.

PATIENT AND METHODS

A 22-month-old Turkish girl from Sweden was born at 42 + 0 weeks through vacuum extraction after severe asphyxia (Apgars: 0, 1, 3). She required cardiopulmonary resuscitation, and spontaneous breathing occurred at 60 min. She was treated with hypothermia for 72 h. She developed seizures at 36 h, managed with phenobarbital and midazolam. Magnetic resonance imaging performed at day 7 showed restricted diffusion in the corpus callosum, subtle changes in globus pallidus, possible thalamic signal changes, and occipital laminar necrosis, consistent with subtotal asphyxia.

The patient was discharged with a diagnosis of severe HIE with risk for cerebral palsy. Over time, global developmental delay and cerebral palsy became evident.

***Corresponding Author:**

Aamir Jalal Al-Mosawi

E-mail: almosawiAJ@yahoo.com

Prior Interventions

Parents sought unregulated stem cell therapy abroad with no benefit, then presented to our clinic after reading about our successful management of a boy with ataxic cerebral palsy from Virginia.

Individualized evidence-based multimodal therapies were recommended based on our extensive published evidence-based experiences with the treatment of cerebral palsy and other neurological conditions.^[1-13,15]

RESULTS

Treatment and Outcomes

First course

- Cerebrolysin 3 mL IM every other day × 15 doses
- Citicoline syrup 300 mg daily
- Outcome: Improved neck and trunk strength, especially during the final week.

Second course

- Intramuscular piracetam 2.5 mL every other day
- Oral citicoline 250 mg daily
- Collagen hydrolysate (CH-Alpha) 2 mL daily
- Outcome: Some cognitive improvements. Increased vocalization; consonant “b” produced daily instead of once weekly.

Third course

- Intramuscular cerebrolysin 3 mL IM every 3rd day × 10 doses
- Intramuscular piracetam 2.5 mL IM every 3rd day × 10 doses (alternate days)
- Oral citicoline 250 mg daily
- CH-Alpha 2 mL daily
- Royal-plus capsule daily
- Outcome: Enhanced cognitive responsiveness, more consistent vocal attempts, improved interaction.

Fourth and fifth courses

- Intramuscular citicoline 2 mL IM every 3rd day (10 doses monthly)

- Intramuscular piracetam 2.5 mL IM every 3rd day (10 doses monthly)
- CH-Alpha 2 mL daily
- Royal-plus capsule daily
- Outcome: Continued gains in awareness, vocalization, and motor engagement. Before treatment, the girl was not crawling and was not able to sit even with support. After treatment, she was crawling for a few centimeters (moving by dragging her tummy on the floor) and was able to sit with support [Figure 1].

DISCUSSION

This case underscores the value of an EBM framework in managing severe cerebral palsy after birth asphyxia.

1. Pathophysiology-based therapy

- Cerebrolysin: Help in improving neuroplasticity and motor outcomes in pediatric cerebral palsy
- Citicoline: Can enhance neuronal membrane repair and has shown cognitive benefits in brain injury




Figure 1: (a) After treatment, she was crawling for a few centimeters. (b) After treatment, she was able to sit with support

- Piracetam: Can enhance motor and cognitive function in children with cerebral palsy
 - Nutritional support (collagen hydrolysate, micronutrients) provided supportive benefit for neuromuscular function.
2. Sequential adaptive therapy
 - Cyclic regimens allowed assessment of measurable outcomes before proceeding
 - Improvements in trunk stability, vocalization, and cognitive interaction were documented over time.
 3. Contrast with unscientific interventions
 - Unregulated stem cell therapy yielded no benefit, consistent with current systematic reviews showing lack of reproducible efficacy
 - In contrast, evidence-based therapy produced tangible functional gains.
 4. Family-centered care
 - Counseling recalibrated expectations away from “cure” promises towards quality of life and functional enhancement.

Cerebrolysin is a mixture of free amino acids (85%) and 15% biologically active low molecular weight amino acid sequences, which include low molecular weight neuro-peptides (Brain-derived neurotrophic factor, glial cell line-derived neurotrophic factor, nerve growth factor, ciliary neurotrophic factor).

Cerebrolysin has been used safely with benefit in a variety of neuro-psychiatric disorders, including idiopathic mental retardation, cerebral palsy, brain atrophy, myelomeningocele, pediatric juvenile spinal muscular atrophy, pediatric Charcot Marie Tooth disease, kernicterus, and agenesis of corpus callosum with colpocephaly.^[16-25]

Citicoline is a safe form of the choline has been increasingly grouped with the water-soluble B vitamins. It has been increasingly used with noticeable benefits in the treatment of several pediatric and neuro-psychiatric disorders, including cerebral palsy, cognitive impairment, autism disorders, Rett syndrome, and kernicterus.^[26,27]

Piracetam beneficial effects on impaired cerebral functions include improving neuronal and cognitive functions, increasing cerebral blood flow and oxygen consumption, improving neurotransmitters

function and brain neurotransmission. Piracetam is not associated with important side effect nor has acute toxicity at the therapeutic doses. Piracetam has been used with important benefits in the treatment of cerebral palsy and other childhood neuro-psychiatric disorders.^[28,29]

CONCLUSION

Severe perinatal asphyxia often results in cerebral palsy with profound disability. This case illustrates how EBM-guided multimodal therapies using neurotrophic, nootropic, and nutritional agents can yield measurable developmental improvements. Rational, evidence-based care should be prioritized over unregulated interventions in the management of pediatric neurological disorders.

ACKNOWLEDGMENT

The author would like to express his gratitude for the mother for kindly accepting publishing the photos of the patient. The author has the copyright of the figures in this paper.

CONFLICTS OF INTEREST

None.

REFERENCES

1. Al-Mosawi AJ. New therapies for the treatment of spastic cerebral palsy. *Med J Clin Trials Case Stud* 2019;3:1-9.
2. Al Mosawi AJ. The pattern of cerebral palsy in Iraqi children. *Med Life Clin* 2019;1:1001.
3. Al Mosawi AJ. New therapies for the treatment of ataxic cerebral palsy caused by kernicterus. *EC Clin Med Case Rep* 2020;3:26-31.
4. Al-Mosawi AJ. The experience with the use of nandrolone decanoate and pyritinol in children with cerebral palsy. *Open Access J Biogeneric Sci Res* 2020;2:1-3.
5. Al-Mosawi AJ. Cerebral palsy: A unique illustrated experience. *Med Res Chron* 2020;7:217-39.
6. Al-Mosawi AJ. The early treatment of a boy from Virginia with ataxic cerebral palsy. *J Pediatr Child Health Issues* 2021;2:1-5.
7. Al-Mosawi AJ. Cerebral palsy, autistic features associated with periventricular white matter hyperintensity on brain magnetic resonance imaging: A diagnostic challenge. *J Pediatr Child Health Issues* 2021;2:1-4.

8. Al-Mosawi AJ. A girl from Canada with severe cerebral palsy associated with hydrocephalus and mutation of kinase d-interacting substrate of 220-KDa (KIDINS220) gene: A new syndrome with unique brain imaging findings and a therapeutic challenge. *J Clin Res Radiol* 2021;4:22-5.
9. Al-Mosawi AJ. Brain imaging abnormalities in cerebral palsy. *J Clin Res Radiol* 2021;4:11-5.
10. Al-Mosawi AJ. A girl from Qatar with post-infantile acquired cerebral palsy caused by submersion injury: A rare etiology and a therapeutic challenge. *Clin Res Clin Trials* 2022;5:1-4.
11. Al-Mosawi AJ. An Indian boy with post-infantile acquired cerebral palsy caused by submersion injury: A rare etiology and a therapeutic challenge. *Case Rep Res Pract Med* 2022;2:41-4.
12. Al-Mosawi AJ. The initial treatment of a girl from Texas with post-infantile acquired cerebral palsy caused by submersion injury. *J Pediatr Neonatal Med* 2022;1:1-4.
13. Al-Mosawi AJ. Cerebral palsy and autism associated with periventricular white matter hyperintensity on brain magnetic resonance imaging: A new disorder and its treatment. *MedPress Psychiatry Behav Sci* 2022;1:1-4.
14. Al-Mosawi AJ. The practice of evidence based medicine. *New Iraqi J Med* 2006;2:8-10.
15. Al-Mosawi AJ. Childhood Lennox-Gastaut syndrome, low set ears, unilateral cryptorchidism: A new variant. *J Clin Images Rep* 2022;1:1-6.
16. Al Mosawi AJ. Clinical uses of cerebrolysin in pediatric neuropsychiatry. *Sci World J Pharm Sci* 2020;1:1-4.
17. Al Mosawi AJ. New medical therapies for the treatment of myelomeningocele. *Surg Med Open Access J* 2019;2:1-4.
18. Al Mosawi AJ. A Novel Therapy for Pediatric Juvenile Spinal Muscular Atrophy. 1st ed. Saarbrücken: LAP Lambert Academic Publishing; 2018.
19. Al Mosawi AJ. The use of cerebrolysin in pediatric Wohlfart Kugelberg Welander syndrome. *MOJ Clin Med Case Rep* 2020;10:20-3.
20. Al Mosawi AJ. A Novel Therapy for Pediatric Charcot Marie Tooth disease. 1st ed. Saarbrücken: LAP Lambert Academic Publishing; 2018.
21. Al Mosawi AJ. The use of cerebrolysin in pediatric charcot marie tooth disease. *J Neurol Res Ther* 2020;3:17-21.
22. Al Mosawi AJ. A Novel Therapeutic Approach for the Neurological Complications of Kernicterus. 1st ed. Saarbrücken: LAP Lambert Academic Publishing; 2018.
23. Al Mosawi AJ. The novel use of cerebrolysin and citicoline in the treatment of kernicterus. *Online J Neurol Brain Disord* 2019;3:208-12.
24. Al-Mosawi AJ. Agenesis of Corpus Callosum with Colpocephaly: A Novel Therapy. 1st ed. Saarbrücken: LAP Lambert Academic Publishing; 2019.
25. Al-Mosawi AJ. The use of piracetam and cerebrolysin in the treatment of agenesis of corpus callosum with colpocephaly. *EC Clin Med Case Rep* 2020;3:1-5.
26. Al Mosawi AJ. Citicoline Research Progress. 1st ed. Saarbrücken: LAP Lambert Academic Publishing; 2019.
27. Al Mosawi AJ. The use of citicoline in pediatric neurology and pediatric psychiatry. *Austin Pediatr* 2019;6:1071-2.
28. Al Mosawi AJ. Recent uses of piracetam in pediatric neurology. *SunKrist Neurol Neurosurg Stroke J* 2020;2:1002.
29. Al Mosawi AJ. Goldberg shprintzen syndrome: A novel therapeutic approach. *EC Clin Med Case Rep* 2020;3:115-23.